Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Chemotherapy with TMCA for Refractory, Metastatic Malignant Melanoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Closed

over 18

NCI-D78-038-066
FCCC-CIRC-77345

Objectives

I.  Evaluate the therapeutic efficacy of oral TMCA as a single agent 
administered daily in the treatment of patients with refractory, metastatic 
malignant melanoma.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Adult patients with measurable, 
histologically proven metastatic malignant melanoma that has failed to respond 
to conventional therapy and applicable Phase II cancer chemotherapeutic 
agents.  Liver, kidney, and bone marrow function must be adequate.  Patients 
must have a life expectancy of at least 3 months.  There may have been no 
prior pelvic irradiation of greater than 2000 rads, and there may have been no 
pelvic radiotherapy or chemotherapy within 4 weeks prior to entry (6 weeks for 
nitrosoureas).

Expected Enrollment

A maximum of 14 patients will be entered.  Protocol closed December 1979.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  TMCA, NSC-36354.

Trial Contact Information

Trial Lead Organizations

Fox Chase Cancer Center - Philadelphia

Robert Bellet, MD, Protocol chair(Contact information may not be current)
Ph: 215-706-3800

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.